Antihistone antibodies in linear scleroderma variants

International Journal of Dermatology

Volumn 45, Issue 11, 2006, Pages 1296-1299

  El azhary, Rokea A ^a   Aponte, Carole C ^a   Nelson, Audrey M ^a   Weaver, Amy L ^a   Homburger, Henry A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CALCIPOTRIOL; CHLOROQUINE; CYCLOPHOSPHAMIDE; HISTONE ANTIBODY; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PREDNISONE; STEROID; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; LIMB; LINEAR SCLERODERMA; MALE; RETROSPECTIVE STUDY; SEROLOGY; TRUNK;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; CHILD; CHILD, PRESCHOOL; FEMALE; HISTONES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SCLERODERMA, LOCALIZED; SKIN;

EID: 33750633016     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02891.x     Document Type: Article

References (14)

1. Jablonska S, Blaszczyk M, Chorzelski TP, et al. Clinical relevance of immunologic findings in scleroderma. Clin Dermatol 1992; 10: 407-421.
2. Nelson AM. Localized forms of sclerodema, including morphea, linear scleroderma, and eosinophilic fasciitis. Curr Opin Rheumatol 1996; 8: 473-476.
3. Falanga V, Medsger TA, Reichlin M. High titers of antibodies to single-stranded DNA in linear scleroderma. Arch Dermatol 1985; 121: 345-347.
4. Falanga V, Medsger TA Jr, Reichlin M, et al. Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986; 104: 849-857.
5. Takehara K, Moroi Y, Nakabayashi Y, et al. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983; 26: 612-616.
6. Rosenberg AM, Uziel Y, Krafchik BR, et al. Antinuclear antibodies in children with localized scleroderma. J Rheumatol 1995; 22: 2337-2343.
7. Sato S, Fujimoto M, Ihn H, et al. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994; 31: 567-571.
8. Sato S, Fujimoto M, Ihn H, et al. Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol 1994; 130: 1273-1277.
9. Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993; 36: 1137-1141.
10. Parodi A, Drosera M, Barbieri L, et al. Antihistone antibodies in scleroderma. Dermatology 1995; 191: 16-18.
11. Hasegawa M, Sato S, Kikuchi K, et al. Antigen specificity of antihistone antibodies in systemic sclerosis. Ann Rheum Dis 1998; 57: 470-475.
12. el-Azhary RA, Aponte CC, Nelson AM. Do antihistone auto-antibodies reflect disease activity in linear scleroderma? Arch Dermatol 2004; 140: 759-760.
13. Uziel Y, Krafchik BR, Feldman B, et al. Serum levels of soluble interleukin-receptor: A marker of disease activity in localized scleroderma. Arthritis Rheum 1994; 37: 898-901.
14. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interluekin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287: 193-197.